Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
empagliflozin + benzbromarone
- Development stage
- Preclinical
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of empagliflozin, an SGLT2 inhibitor, and benzbromarone, a URAT1 inhibitor. This combination has been studied for its effects on uric acid metabolism and excretion. Empagliflozin works by inhibiting SGLT2 in the kidneys, preventing glucose reabsorption and secondarily enhancing uric acid excretion. Benzbromarone primarily inhibits URAT1, directly increasing uric acid excretion. The combination has been investigated for potential synergistic effects on reducing serum uric acid levels.
02
Targets
SGLT2 (Sodium-glucose cotransporter protein subunit 2)URAT1 (Uric Acid Transporter 1)
Beyond the preview
Go deeper on empagliflozin + benzbromarone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on empagliflozin + benzbromarone.